Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease
Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and efficacy of pegunigalsidase alfa in
Japanese patients (adults and adolescents) affected by Fabry disease. It is planned of a
total of approximately 18-20 male and female Fabry disease patients between the ages of 13
and 60 years to be part of the study. The study is conducted in Japan.